Cavin-1 regulates caveolae-mediated LDL transcytosis: crosstalk in an AMPK/eNOS/ NF-κB/Sp1 loop.

Oncotarget

Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430077, China.

Published: November 2017

Caveolae are specialized lipid rafts structure in the cell membrane and critical for regulating endothelial functions, transcytosis of macromolecules like low density lipoprotein (LDL) . Specifically, the organization and functions of caveolae are mediated by structure protein (caveolin-1) and adapter protein (cavin-1). The pathogenic role of caveolin-1 is well studied; nevertheless, mechanisms whereby cavin-1 regulates signaling transduction remain poorly understood. The aim of this study was designed to explore the role of cavin-1 in caveolae-mediated LDL transcytosis across endothelial cells. We reported here that cavin-1 knockdown mediated by small interfering RNA (siRNA) caused a significant decrease of LDL transcytosis. Moreover, cavin-1 knockdown increased the activity of endothelial nitric oxide synthase (eNOS) and the production of nitric oxide (NO). Consequently, an eNOS inhibitor, N-Nitro-L-Arginine Methyl Ester (L-NAME), not only suppressed the activity of specificity protein (Sp1) and nuclear factor kappa B (NF-κB), but also inhibited both activities via activating adenosine 5'-monophosphate- activated protein kinase (AMPK). In conclusion, we proposed an AMPK/eNOS/NF-κB/Sp1 circuit loop was formed to regulate caveolae residing proteins' expression, LDL receptor (LDLR), caveolin-1, eNOS, thereby to regulate caveolae-mediated LDL transcytosis in endothelial cells.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732781PMC
http://dx.doi.org/10.18632/oncotarget.21944DOI Listing

Publication Analysis

Top Keywords

ldl transcytosis
16
caveolae-mediated ldl
12
cavin-1 regulates
8
transcytosis endothelial
8
endothelial cells
8
cavin-1 knockdown
8
nitric oxide
8
cavin-1
6
ldl
6
transcytosis
5

Similar Publications

Apolipoprotein B-containing lipoproteins in atherogenesis.

Nat Rev Cardiol

January 2025

Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Article Synopsis
  • ApoB is the key protein found in LDL and other lipoproteins, playing a major role in their formation and link to atherosclerosis.
  • LDL contributes to plaque formation in arteries by entering the wall and triggering inflammatory responses through interaction with other molecules, leading to harmful processes like foam cell formation.
  • Research has identified potential interventions to combat atherosclerosis by lowering lipoprotein levels and addressing the inflammatory responses in the arterial wall.
View Article and Find Full Text PDF

Siglec-5 as a novel receptor mediates endothelial cells oxLDL transcytosis to promote atherosclerosis.

Transl Res

December 2024

Department of Endocrinology, Institute of Geriatric Medicine, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology. Wuhan 430077, China. Electronic address:

Article Synopsis
  • Too much oxidized bad cholesterol (oxLDL) builds up in blood vessels, causing foam cells and heart problems known as atherosclerosis.
  • Researchers found that a protein called Siglec-5 helps this bad cholesterol stick to cells and encourages heart disease.
  • They tested how Siglec-5 works in mice and discovered that when they increased Siglec-5, it made heart issues worse, but blocking or reducing Siglec-5 helped improve the problem.
View Article and Find Full Text PDF

IL-1β Induces LDL Transcytosis by a Novel Pathway Involving LDLR and Rab27a.

Arterioscler Thromb Vasc Biol

September 2024

Keenan Centre for Biomedical Research, St. Michael's Hospital, Toronto, ON, Canada (E.J., T.W.W.H., C.W., W.L.L.).

Background: In early atherosclerosis, circulating LDLs (low-density lipoproteins) traverse individual endothelial cells by an active process termed transcytosis. The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) treated advanced atherosclerosis using a blocking antibody for IL-1β (interleukin-1β); this significantly reduced cardiovascular events. However, whether IL-1β regulates early disease, particularly LDL transcytosis, remains unknown.

View Article and Find Full Text PDF

Imbalance of APOB Lipoproteins and Large HDL in Type 1 Diabetes Drives Atherosclerosis.

Circ Res

July 2024

Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, UW Medicine Diabetes Institute (V.K., Y.H., F.K., M.S.-A., J.E.K., B.S., J.W.H., T.V., K.E.B.).

Background: Individuals with type 1 diabetes (T1D) generally have normal or even higher HDL (high-density lipoprotein)-cholesterol levels than people without diabetes yet are at increased risk for atherosclerotic cardiovascular disease (CVD). Human HDL is a complex mixture of particles that can vary in cholesterol content by >2-fold. To investigate if specific HDL subspecies contribute to the increased atherosclerosis associated with T1D, we created mouse models of T1D that exhibit human-like HDL subspecies.

View Article and Find Full Text PDF

Atherosclerosis begins with the infiltration of cholesterol-containing lipoproteins into the arterial wall. White blood cell (WBC)-associated inflammation follows. Despite decades of research using genetic and pharmacologic methods to alter WBC function, in humans, the most effective method to prevent the initiation and progression of disease remains low-density lipoprotein (LDL) reduction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!